New shot could tame peanut allergies in one dose

NCT ID NCT06331728

Completed Disease control Sponsor: IgGenix Australia Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a single injection of a new drug called IGNX001 in 32 adults and teens with peanut allergies. The main goal was to check safety and how the body processes the drug. Participants received either the drug or a placebo, and researchers monitored for side effects and allergic reactions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IGNX001
What this could lead to: If successful, this could lead to a single-dose treatment that reduces peanut allergy reactions, offering a new option for managing this condition.
What could go wrong: This is an early Phase 1 trial with only 32 participants, focused on safety. It may not show effectiveness, and side effects or lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEANUT ALLERGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

food allergy Peanut Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PEANUT ALLERGY

Contacts and locations

Locations

Fiona Stanley Hospital

Murdoch, Western Australia, 6150, Australia
Monash Health, Sleep, Allergy, and Immunology

Clayton, Victoria, 3168, Australia
Royal Melbourne Hospital

Parkville, Victoria, 3050, Australia
St Vincent's Sydney

Darlinghurst, New South Wales, 2010, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.